Clearmind Medicine (CMND) said Friday it has added Hadassah-University Medical Center in Jerusalem as a new site for its ongoing clinical trial for its experimental alcohol use disorder treatment.
The study is testing CMND-100, an experimental oral treatment developed to help people with alcohol use disorder. Researchers will also observe whether the drug helps reduce alcohol cravings and drinking habits, the company said.
The new site will be led by Prof. Yossi Karko and will join other trial partners, including Yale, Johns Hopkins, Tel Aviv Sourasky Medical Center and IMCA.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.